Coronavirus Notebook: EMA Begins Assessing AZ’s Evusheld, Apeiron Starts Phase I Trial Of Inhaled APN01
The UK has explained its strategy for administering COVID-19 vaccines to people who have been partially immunized abroad.
You may also be interested in...
Biocon management signals the potential of its partnered entry with Serum Institute and Adagio Therapeutics into the communicable diseases segment. Continuing large supply opportunities for COVID-19 vaccines and prospects for boosters, alongside the promising profile of the neutralizing antibody being developed by its US-based partner, also bode well.
Coronavirus Notebook: CEPI Calls For Reduced-Dose Booster Trials, Regeneron’s Ronapreve Filed In EU.
EU health ministers are discussing booster and additional vaccines as well as COVID-19-related medicines shortages, and England is to offer approved vaccines to clinical trialists to ease international travel.
The European drugs regulator has given an overview of progress with the assessment of new vaccine candidates, additional and booster vaccines, and the use of vaccines in younger age groups.